Movano Health (NASDAQ: MOVE) is a publicly traded Health & Biometric Sensing company founded in 2018 and based in Pleasanton, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Corvex (formerly Movano) reported Q2 2026 revenue of $3.8 million, with $4.3 million in the six-month period. This marks the first full reporting quarter following the March 2026 merger that transformed the company from a legacy healthcare device business to a GPU-accelerated AI infrastructure platform. The company posted a net loss of $12.8 million in Q2 ($(5.12) per share) and $(17.8) million year-to-date. Adjusted EBITDA was $(3.2) million and $(4.8) million for the same periods. Deferred revenue reached $3.7 million at June 30, reflecting contracted AI compute capacity. Operationally, contracted annualized recurring revenue on live compute stood at approximately $22 million as of August 14. The company reported $21.7 million in cash, extinguished a $4.4 million bridge loan in June via asset transfer, and completed a capital structure simplification in July. Corvex Token Factory moved into closed alpha; additional software releases are planned for Q3 and Q4 2026.
No articles ingested yet for Movano Health. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
The Evie Ring is Movano's women-first smart ring, designed with an open, gapped band that accommodates daily finger-size fluctuations rather than a fully closed circle. It tracks activity, sleep, heart rate, blood oxygen, resting heart rate, skin temperature, and menstrual-cycle data, and its insights engine surfaces correlations over time between cycle phase and metrics like heart health, mood, energy, and sleep. The product is aimed squarely at women's health and wellness, a segment the company argues mainstream wearables have historically treated as an afterthought.
Evie Med is Movano's medical-grade variant of the Evie Ring, combining wellness tracking with regulated health measurements. The company completed hypoxia trials with UCSF supporting the accuracy of its pulse-oximeter (SpO2 and pulse) feature and has pursued FDA clearance to move the device toward medical-device status. Built on Movano's proprietary radio-frequency system-on-chip, Evie Med is intended to extend ring-based monitoring beyond consumer wellness into clinically validated metrics, part of the company's broader roadmap toward cuffless blood pressure and non-invasive glucose sensing.